A Phase 2 interventional study of Gaboxadol and Placebo in Fragile X Syndrome, sponsored by Craig Erickson. Completed at 1 site in United States. Open to male participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Craig Erickson · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Fragile X Syndrome with a site in United States — 11 open to participants now, 16 under way, 2 of them phase 3. Fragile X Syndrome · United States.
Among the 82 studies in Fragile X Syndrome with a site in United States, this one is the 62nd largest by enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2024, is one of 28 in phase 2, and was the 75th registered.
115 studies on the registry are indexed under Fragile X Syndrome; 25 are open to participants now.
Browse Fragile X Syndrome studies →11 of the 82 studies in Fragile X Syndrome with a site in United States are open now. Recruiting first, the newest first:
Healing Hope International · Sites in United States
Ages 4–12
Mirum Pharmaceuticals, Inc. · Sites in United States, Spain
Ages 13–45 · Men only
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+ · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 5–10 · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 6 mo–26 mo · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Fragile X Syndrome studies recruiting now, 5 (28%) set no upper age limit and 13 (72%) stop at 75 or younger; 15 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 40 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 36 · Phase 3 11 · Phase 4 2
First in 2002; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 54 across 92 interventional studies indexed under Fragile X Syndrome.
Median enrollment 60 across the 68 interventional studies, 100 across the 12 observational. Of the 58 that completed or were terminated, 22 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 82 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Craig Erickson as lead sponsor.
Craig Erickson has 1 study filed under Fragile X Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Fragile X Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05367960Phase 3Tetra Discovery PartnersAn Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome | 2027-09-30 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06139172Rush University Medical CenterWeb Intervention for Parents of Youth With Genetic Syndromes (WINGS) | 2026-12 |
| NCT06560242Children's Hospital Medical Center, CincinnatiTracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG- Infant | 2027-03-01 |
| NCT05957549Children's Hospital Medical Center, CincinnatiTracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG-Preschool Age | 2027-03-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 82 studies in Fragile X Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single dose, placebo-controlled study. Male subjects aged 18 to 40 years (inclusive) with a diagnosis of FXS. Eligible subjects may enroll in this study comprised of two in home and two in clinic visits each 14 days apart, for a total of four visits. Subjects will be given single dose gaboxadol (10 mg) or matched placebo at each of these visits to take orally. Thus, all enrolled subjects will receive placebo at home and in clinic and receive gaboxadol at home and in clinic in a blinded fashion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals in this condition received Placebo in lab, Gaboxadol in home, Gaboxadol in lab, then Placebo in home.
Drug: Gaboxadol · Drug: Placebo
Individuals in this condition received Gaboxadol in lab, Gaboxadol in home, Placebo in lab, then Placebo in home.
Drug: Gaboxadol · Drug: Placebo
Individuals in this condition received Placebo in lab, Placebo in home, Gaboxadol in lab, then Gaboxadol in home.
Drug: Gaboxadol · Drug: Placebo
Individuals in this condition received Gaboxadol in lab, Placebo in home, Placebo in lab, then Gaboxadol in home.
Drug: Gaboxadol · Drug: Placebo
Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)
Two placebo capsules
Target Engagement of Gaboxadol Treatment on EEG Power
Changes in EEG recordings with gaboxadol treatment (assessed at pre-dose, 60 minutes post-dose, average response across home and lab reported). compared with pre-dose on resting theta, alpha and gamma band absolute power. Absolute power measures reflect the median power averaged across 129 electrodes in μV²/Hz. Means are presented using the average of home and lab values.
Time frame: Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42
Target Engagement of Gaboxadol Treatment on Auditory Chirp
Changes in EEG recordings with gaboxadol treatment (60-90 minutes post-dose compared with pre-dose on brain response to auditory chirp stimuli), as measured by intertrial phase coherence (ITC). Means are presented using the average of home and lab values.
Time frame: Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42
To Investigate the Feasibility of Home Research Visits and Procedures in Adult Males With FXS
Quality and test-retest reliability of assessments performed at home compared with the hospital setting. This includes blood testing for Fragile X messenger ribonucleoprotein (FMRP: range of 0-40 picomolar) and eye-tracking of eye gaze to eye regions when viewing faces (range of value from 0 percent to 100 percent; higher values are associated with a neurotypical phenotype).
Time frame: Pre-dose, 60 minutes post-dose
To Investigate the Feasibility of High Density EEG Recording at Home in Adult Males With FXS
This endpoint examined the reliability of pre-dose resting-state EEG absolute power estimates between in-lab and in-home assessments using intraclass correlation (ICC). ICCs were calculated separately for 129 electrodes using absolute power estimates (μV²/Hz). The reported ICC represents the mean ICC across electrodes, with the standard deviation reflecting variability in ICC values across electrodes. whole-head, pre-dose resting state EEG power estimates from data collected in-lab vs in-home using intraclass correlation (ICC).
Time frame: Pre-dose, across four sessions (2 in-lab, 2 in-home), up to day 42
To Potentially Explore the Pharmacokinetics of Gaboxadol Treatment in Single-dose Trial Design
PK profile (the level of gaboxadol in human plasma) will be obtained at 60 +/- 10 minutes post-dose only).
Time frame: Sixty minutes post-dose on 4 study visits, up to day 42
To Investigate the Effect of Gaboxadol Treatment on Neuropsychological Assessments
Changes in cognitive and neuropsychological assessment measures with gaboxadol treatment (RBANS List Learning). During the RBANS List Learning subtests, participants listen to a list of 10 words and repeat back as many as they can remember four times, for a maximum score of 40. Change scores were calculated by subtracting pre-dose words remembered from post-dose words remembered, with positive scores meaning an improvement in memory.
Time frame: Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42
To Investigate the Effect of Gaboxadol Treatment on Eye Tracking Assessments
Change in eye tracking outcomes (60-90 minutes post-dose compared to pre-dose on percent viewing of social versus geometric scene
Time frame: Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42
To Investigate the Effect of Gaboxadol Treatment on Clinician-rated Measures
Score on the Clinical Global Impressions - Improvement (CGI-I) scale, a clinician rating scale with "1" anchored to "very much improved" and "7" anchored to "very much worse."
Time frame: Post-dose on 4 study visits, up to day 42
To Determine Whether FMRP Levels Predict Treatment Response
Relationship between FMRP (Fragile X messenger ribonucleoprotein) level and degree of change (baseline/screen to post-dose) across measures
Time frame: Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42
| Milestone | Placebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in Home | Gaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in Home | Placebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in Home | Gaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in Home |
|---|---|---|---|---|
| Started | 2 | 3 | 3 | 2 |
| Completed | 2 | 3 | 3 | 2 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Placebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in Home | Gaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in Home | Placebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in Home | Gaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in Home |
|---|---|---|---|---|
| Started | 2 | 3 | 3 | 2 |
| Completed | 2 | 3 | 3 | 2 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Placebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in Home | Gaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in Home | Placebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in Home | Gaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in Home |
|---|---|---|---|---|
| Started | 2 | 3 | 3 | 2 |
| Completed | 2 | 3 | 3 | 2 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Placebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in Home | Gaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in Home | Placebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in Home | Gaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in Home |
|---|---|---|---|---|
| Started | 2 | 3 | 3 | 2 |
| Completed | 2 | 3 | 3 | 2 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Placebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in Home | Gaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in Home | Placebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in Home | Gaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in Home |
|---|---|---|---|---|
| Started | 2 | 3 | 3 | 2 |
| Completed | 2 | 3 | 3 | 2 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Placebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in Home | Gaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in Home | Placebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in Home | Gaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in Home |
|---|---|---|---|---|
| Started | 2 | 3 | 3 | 2 |
| Completed | 2 | 3 | 3 | 2 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Placebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in Home | Gaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in Home | Placebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in Home | Gaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in Home |
|---|---|---|---|---|
| Started | 2 | 3 | 3 | 2 |
| Completed | 2 | 3 | 3 | 2 |
| Not completed | 0 | 0 | 0 | 0 |
Changes in EEG recordings with gaboxadol treatment (assessed at pre-dose, 60 minutes post-dose, average response across home and lab reported). compared with pre-dose on resting theta, alpha and gamma band absolute power. Absolute power measures reflect the median power averaged across 129 electrodes in μV²/Hz. Means are presented using the average of home and lab values.
| μV²/Hz | Gaboxadol | Placebo |
|---|---|---|
| Theta pre-dose | 2.19 ± 1.85 | 2.07 ± 2.09 |
| Theta post-dose | 4.06 ± 2.88 | 2.07 ± 2.06 |
| Alpha pre-dose | -1.01 ± 1.88 | -1.32 ± 1.84 |
| Alpha post-dose | -0.18 ± 2.02 | -1.10 ± 1.99 |
| Gamma pre-dose | -8.78 ± 2.73 | -8.81 ± 2.41 |
| Gamma post-dose | -8.95 ± 2.81 | -8.87 ± 2.32 |
Quality and test-retest reliability of assessments performed at home compared with the hospital setting. This includes blood testing for Fragile X messenger ribonucleoprotein (FMRP: range of 0-40 picomolar) and eye-tracking of eye gaze to eye regions when viewing faces (range of value from 0 percent to 100 percent; higher values are associated with a neurotypical phenotype).
No measurements were reported for this outcome.
This endpoint examined the reliability of pre-dose resting-state EEG absolute power estimates between in-lab and in-home assessments using intraclass correlation (ICC). ICCs were calculated separately for 129 electrodes using absolute power estimates (μV²/Hz). The reported ICC represents the mean ICC across electrodes, with the standard deviation reflecting variability in ICC values across electrodes. whole-head, pre-dose resting state EEG power estimates from data collected in-lab vs in-home using intraclass correlation (ICC).
| correlation coefficient | All Study Participants |
|---|---|
| Delta ICC | 0.77 ± .11 |
| Theta ICC | 0.83 ± 0.10 |
| Alpha ICC | 0.86 ± .10 |
| Beta ICC | .75 ± .17 |
| Gamma ICC | .67 ± .14 |
PK profile (the level of gaboxadol in human plasma) will be obtained at 60 +/- 10 minutes post-dose only).
Results for this outcome have not been posted.
Changes in cognitive and neuropsychological assessment measures with gaboxadol treatment (RBANS List Learning). During the RBANS List Learning subtests, participants listen to a list of 10 words and repeat back as many as they can remember four times, for a maximum score of 40. Change scores were calculated by subtracting pre-dose words remembered from post-dose words remembered, with positive scores meaning an improvement in memory.
| Change in words remembered | Gaboxadol | Placebo |
|---|---|---|
| To Investigate the Effect of Gaboxadol Treatment on Neuropsychological Assessments | 2.38 ± 1.46 | -0.5 ± 1.46 |
Change in eye tracking outcomes (60-90 minutes post-dose compared to pre-dose on percent viewing of social versus geometric scene
Results for this outcome have not been posted.
Score on the Clinical Global Impressions - Improvement (CGI-I) scale, a clinician rating scale with "1" anchored to "very much improved" and "7" anchored to "very much worse."
| sessions | Gaboxadol | Placebo |
|---|---|---|
| Post dose: CGI rating of 1 | 0 | 0 |
| Post dose: CGI rating of 2 | 0 | 0 |
| Post dose: CGI rating of 3 | 2 | 0 |
| Post dose: CGI rating of 4 | 18 | 20 |
| Post dose: CGI rating of 5 | 0 | 0 |
| Post dose: CGI rating of 6 | 0 | 0 |
| Post dose: CGI rating of 7 | 0 | 0 |
Relationship between FMRP (Fragile X messenger ribonucleoprotein) level and degree of change (baseline/screen to post-dose) across measures
Results for this outcome have not been posted.
Changes in EEG recordings with gaboxadol treatment (60-90 minutes post-dose compared with pre-dose on brain response to auditory chirp stimuli), as measured by intertrial phase coherence (ITC). Means are presented using the average of home and lab values.
| unitless | Gaboxadol | Placebo |
|---|---|---|
| Chirp ITC pre-dose | 42.8 ± 22.7 | 43.1 ± 19.7 |
| Chirp ITC post-dose | 38.4 ± 19.6 | 41.2 ± 18.8 |
Collected over From enrollment until last safety call, on day 49 (+/- 5 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gaboxadol in Home | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Gaboxadol in Lab | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Placebo in Home | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Placebo in Lab | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Event | Gaboxadol in Home | Gaboxadol in Lab | Placebo in Home | Placebo in Lab |
|---|---|---|---|---|
| FatigueGeneral disorders | 2/10 | 4/10 | 0/10 | 1/10 |
| FeverGeneral disorders | 0/10 | 1/10 | 0/10 | 0/10 |
| Elevated heart rateCardiac disorders | 0/10 | 0/10 | 0/10 | 1/10 |
| Emotional disturbance (anxiety, aggression, crying)Psychiatric disorders | 0/10 | 0/10 | 0/10 | 1/10 |
| Age, Categorical(Participants) | Placebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in Home | Gaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in Home | Placebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in Home | Gaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in Home | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 3 | 3 | 2 | 10 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Placebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in Home | Gaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in Home | Placebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in Home | Gaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in Home | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 2 | 3 | 3 | 2 | 10 |
| Race (NIH/OMB)(Participants) | Placebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in Home | Gaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in Home | Placebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in Home | Gaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in Home | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 2 | 3 | 3 | 2 | 10 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Placebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in Home | Gaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in Home | Placebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in Home | Gaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in Home | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 | 0 | 2 |
| Not Hispanic or Latino | 1 | 3 | 2 | 2 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2024 to primary completion in May 2025, 15 months.
Results were first posted in Sep 2026, 1 year 4 months after primary completion.
Of 15 phase 2 interventional studies under Fragile X Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 37. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gaboxadol